Kornimate/medical-research-clean huggingface dataset:
hiv education kit for adolescents (pencegahan hiv di kalangan remaja), prem-kit

Conditions: Human Immunodeficiency Virus

Summary: the goal of this community trial is to provide hiv education based on the newly developed hiv education kit (prem-kit) and evaluate the knowledge, attitude and practices related to hiv prevention among the late adolescents (aged 18 to 19 years old) in malaysia. the main question it aims to answer is does the prem-kit improve the knowledge, attitude and practices related to hiv prevention among the adolescent? participants will be asked to: * answer a questionnaire as a baseline screening to determine their knowledge, attitude and practices related to hiv prevention. * using prem-kit, they will participate in a series of health education sessions. there will be three sessions in total which will be delivered two weekly apart. each of the sessions will take approximately 20 minutes duration. * following the last session (third session), participants will have to answer the same questionnaire ; once immediately after the last session, once at 3-months post-intervention, and lastly, at 4-months post-intervention. researchers will compare participants who received the existing basic science and biology module to see if there is any improvement in the knowledge, attitude and practices related to hiv prevention.


Eligibility criteria:
inclusion criteria: * late adolescents aged 18 - 19 years * student who attends health science diploma course in the year 2023 * malaysian citizen exclusion criteria: * student who refused to participate in the study * student who is absent on the first session of the intervention * student who does not understand the malay language

Keywords: human immunodeficiency virus adolescents information-motivation-behavioral skills model
four-hour evaluation of a medical food in subjects with type 2 diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of this study is to demonstrate the efficacy of a nutritional formula in patients with type 2 diabetes.


Eligibility criteria:
inclusion criteria: 1. subject has type 2 diabetes. 2. subject is over 18 years of age. 3. subject is a male, or a non-pregnant, non-lactating female. 4. subject's bmi is \> 20 kg/m2 and \< 40 kg/m2. 5. subject's hba1c level is 6.5 - 11%. 6. if on a chronic thyroid medication or hormone replacement therapy, subject has been on constant dosage for at least two months prior to screening visit. 7. subject's weight is stable for the past two months prior to screening visit. exclusion criteria: 1. subject uses exogenous insulin, byetta or alpha-glucosidase inhibitor for glucose control. 2. subject has type 1 diabetes. 3. subject has history of diabetic ketoacidosis. 4. subject has the following: current infection ; has had inpatient surgery or received systemic corticosteroid treatment in the last 3 months; or antibiotics in the last 3 weeks prior to screening. 5. subject has an active malignancy. 6. subject has had significant cardiovascular event \<6 months prior to study entry or history of congestive heart failure. 7. subject has end stage organ failure. 8. subject has history of severe gastroparesis, renal or hepatic disease. 9. subject has an active metabolic, hepatic, or gastrointestinal disease or condition that may interfere with nutrient absorption, distribution, metabolism, or excretion, excluding diabetes. 10. subject has a chronic, contagious, infectious disease. 11. taking daily medications at doses that would interfere with nutrient absorption, metabolism, excretion, gastric motility, or blood glucose. 12. subject has fainted or experienced other adverse event in response to blood collection prior to enrollment into this study. 13. clotting or bleeding disorders. 14. allergic or intolerant to any ingredient found in the test meal.
bone marrow derived adult liver stem cell recruitment after major liver resections: correlation with liver regeneration and hepatic function

Conditions: Liver Cancer

Summary: the results of this study may or may not establish useful baseline data, which will help us understand how bone marrow derived adult liver stem cells behave in normal healthy adults/volunteers (the control group), and in patients undergoing liver surgery. the bone marrow is located within your bones and is the organ which is responsible to produce blood cells and stem cells. bone marrow derived adult liver stem cells are normal cells in your bone marrow. these liver stem cells have the capacity to regenerate or in other words to rebuild the liver after liver surgery, a process called liver regeneration. these cells are very important for the liver to regrow its tissue after liver surgery. these cells are thought to be activated in times of need by the liver. situations like liver surgery are one of these occasions when the liver will need the "extra help" from these stem cells. the results of this study will establish the baseline data necessary for the understanding of how to harness the ability of these stem cells in times of liver surgery. improvements in the ability of the liver to regrow after surgery is thought to decrease complications related to liver surgery. harnessing this unique ability of stem cells may be utilized in the future to enhance the regrowing process of liver tissue after liver surgery, called liver regeneration.


Eligibility criteria:
inclusion criteria: * adults (≥ or equal to 18 years old). * patients scheduled for resection of 3 or more liver segments for any indication, with or without other planned procedures. or * normal healthy volunteers (control). exclusion criteria: * chemotherapy or gcsf treatment in the preceding 4 weeks. * child's classification b or above. * presence of active infection. * history of lymphoma or leukemia. * normal healthy volunteers who underwent chemotherapy treatment at any stage of their life will be excluded. * normal healthy volunteers who are under any active treatment for any active illness will be excluded.

Keywords: liver resection
comprehensive analysis of the program:salud escolar

Conditions: Obesity

Summary: the purpose of this study is to comprehensively evaluate salud escolar (school health), a program led by the mexican ministries of health and education. this comprehensive evaluation considers a design, implementation, results, and impact evaluation of salud escolar.

this study aims is to comprehensively analyze the design, implementation, results, and impact of salud escolar, a program led by the mexican ministries of health and education, during the first phase of implementation, from august 2020 to july 2021. salud escolar considers the world health organization (who) health promoting framework to foster a healthy environment and enhance children's physical activity, healthy eating and hydration. salud escolar consists on several activities aligned in the following components: healthy eating, healthy hydration, physical activity and additional cross sectional strategies. the first phase of implementation will be conducted in a total of 58 schools located in mexico city purposively selected by the ministry of education. the design evaluation will use available policy documents and program implementation guidelines, scientific literature, to investigate wether the design of salud escolar is adequate to achieve the proposed objectives. the implementation evaluation will be conducted in a sub-sample of 6 intervention schools using qualitative methodologies among key informants. the results evaluation will be conducted in the 58 intervention schools and pre-post changes in self-reported knowledge, attitudes and practices related to healthy eating, hydration and being physically active will be measured. the impact evaluation aims to evaluate the effect of salud escolar on the consumption of fruits, vegetables and plain water and daily moderate to vigorous physical activity. a sample of 1200 children (6-12 years old) in 15 intervention schools- randomly selected from the sample of 58 intervention schools-, and 15 comparison schools - randomly selected from the waiting list of available schools in the city will be recruited. based on the results derived from this analysis, a set of recommendations will be provided to improve the feasibility of scaling up the program at the national level during the second and third phases of salud escolar.

Eligibility criteria:
school inclusion criteria: * public school * minimum of 200 children exclusion criteria: + none children inclusion criteria: * aged 6 to 12 years * grades 1-6 * attending school on the day of recruitment at the included schools in mexico city, mexico during the school-year 2020/2021 exclusion criteria: + schoolchildren with a physical or mental disability not able to participate in daily physical activity or other intervention components or measures.

Keywords: physical activity healthy eating hydration school intervention health policy
omalizumab for the treatment of food allergy in patients with elevated total ige levels

Conditions: Food Hypersensitivity

Summary: in this project, the investigators would like to learn if 24 weeks (about 5 and a half months) of omalizumab injections, given every 2 weeks, will be safe and effective for food allergic people who have a total immunoglobulin e (ige) above the current fda approved dosing regimen enabling a person to increase tolerance to the food(s) that the person is allergic to. the investigators would also like to learn if participants who demonstrate increased tolerance to food after 24 weeks of omalizumab, can introduce the food into the diet utilizing an additional 8 weeks (about 2 months) of twice weekly omalizumab injections.


Eligibility criteria:
inclusion criteria: * age 1 to 55 years * a positive prick skin test (pst) with a wheal ≥ 6 mm to at least one of the relevant foods (peanut, cashew, walnut, egg, milk, or wheat) * positive food-specific ige (≥2.0 kilo units of allergen-specific ige per liter (kua/l)) to at least one of the study specific foods * a weight / ige level that would have excluded the participant from the outmatch study based on the dosing table noted above * positive double-blind, placebo-controlled food challenge (dbpcfc) to one of the relevant foods at a cumulative dose of ≤144 mg (maximum tolerated dose ≤30 mg) exclusion criteria: * clinically significant laboratory abnormalities at screening. * dose-limiting symptoms during the blinded food challenge to placebo during the screening dbpcfc. * poorly controlled or severe asthma/wheezing at screening * history of severe anaphylaxis to participant-specific foods that will be used in this study, defined as neurological compromise or requiring intubation. * treatment with a burst of oral, intramuscular (im), or intravenous (iv) steroids of more than two days for an indication other than asthma/wheezing within 30 days of screening. * currently receiving oral, im, or iv corticosteroids, tricyclic antidepressants, or β-blockers. * past or current history of eosinophilic gastrointestinal disease within three years of screening. * past or current history of cancer, or currently being investigated for possible cancer. * past or current history of any food immunotherapy (e.g., oral immunotherapy (oit), sublingual immunotherapy (slit), epicutaneous immunotherapy (epit) within 6 months of screening. * treatment with monoclonal antibody therapy, such as omalizumab, dupilumab, benralizumab, mepolizumab, reslizumab, tezepelumab, or other immunomodulatory therapy within 6 months of screening. * inability to discontinue antihistamines for minimum wash-out periods required for skin prick tests (spts) or oral food challenges (ofcs). * pregnant or breastfeeding, or intending to become pregnant during the study * evidence of clinically significant chronic disease.

Keywords: omalizumab
closure of peritoneum at cesarean section and postoperative adhesion

Conditions: Cesarean Section; Adhesions

Summary: objective: to determine the effect of non-closure of the visceral and parietal peritoneum during cesarean section on the formation of adhesions. study design: a prospective randomized trial of 533 women undergoing primary cesarean section; 256 were randomized to non closure and 277 to closure of the peritoneum. at a subsequent cesarean,he presence of adhesions and their severity was evaluated at several sites: between the layers of the abdominal wall, between the bladder and the abdominal wall, between bladder and uterus, between the uterus and the abdominal wall, and between the bowels and the pelvic organs. a cumulative adhesion score was calculated.


Eligibility criteria:
inclusion criteria: * women undergoing primary cs exclusion criteria: * lack of consent by the patient or an urgent cesarean not allowing time to elicit an informed consent * previous pelvic or abdominal surgery

Keywords: formation of adhesions assessed at subsequent cs
non-invasive ventilation in preterm infants

Conditions: Premature Birth; Respiratory Distress Syndrome; Ventilator Lung; Newborn

Summary: this is a prospective, observational cohort study. for the study part on noninvasive neurally adjusted ventilatory assist (niv-nava) the design is interventional. for all participants prospective data collection will be conducted by chart review and by downloading ventilatory data from the ventilator. a registration of respiratory severity score will be done by a caregiver during the weaning period. this consists of a visual assessment of the work of breathing every 2 hours. for participants on niv-nava consenting to the interventional part of the study a titration procedure will be conducted, afterwards serial electrical impedance tomography and lung and diaphragm ultrasound measurements will be done.


Eligibility criteria:
inclusion criteria: * preterm infants (\ 2 liters/min).the support can be given as primary respiratory support or as respiratory support after weaning from invasive ventilation (= after extubation). * infants can only be enrolled after written and signed informed consent by the parents. exclusion criteria: * infant born after a gestational age of 37 weeks or more. * infants with major congenital malformations or chromosomal abnormalities (eg trisomy 18, congenital diaphragmatic hernia...)
effect of nitrous oxide in treating neuropathic pain: a study in chronic low back pain patients

Conditions: Low Back Pain; Radiating Pain

Summary: epidural injection will be completed under fluoroscopy and all patients will receive 1-4 mg of midazolam for relaxation before procedure and, if needed, 50-100 mcg of fentanyl intravenous (iv). radiopaque contrast (omnipaque 300), for confirming the epidural position of the needle, steroids and local anesthetic agents will be used according to the physician performing the block and will not be controlled by the study. patients will be randomly assigned to receive either inhaled entonox along with the interventional block they are scheduled for or oxygen. they will be blinded about the treatment they are receiving. those randomized to entonox will inhale the gas through a mouthpiece throughout the procedure and also continue to receive it for a total of 4 hours in the recovery. those randomized to the oxygen group will receive oxygen through a similar mouthpiece for the entire duration of the procedure and recovery for 4 hours. following completion of procedure the patient will be transferred to recovery and monitored for 3-5 hours then discharged home with instructions. possible side effects will be monitored and recorded, pain score of patient will be recorded before discharge. all the patients will receive standard instructions regarding physical back exercises. this will be repeated for every procedure up to maximum of three blocks. the patients will be followed during each block and over a period of 1, 3, 6 and 12 months and on each follow-up visit will complete computerized set of questionnaires as they did before the procedure. the patients charts will be then reviewed for one year after the initial procedure to determine if further epidural steroid injections or surgery for the presenting problem were required. it is anticipated that the appropriate number of patients will be enrolled within six months of study initiation.


Eligibility criteria:
inclusion criteria: * 18 to 80 years old at time of the first procedure * male or female * history of chronic low back pain for longer than 6 months due to radiculopathy, symptomatic spinal canal stenosis, disc prolapse, postlaminectomy syndrome * magnetic resonance imaging or electromyographic evidence of nerve root damage * leeds assessment of neuropathic symptoms and signs (lanss) score of \>12 * no or minimal evidence of facet joint pathology exclusion criteria: * known contraindications for epidural injection * patients with ongoing workers' compensation claims * unstable or heavy opioid use (400 mg of morphine equivalents daily), * psychiatric disorders * medical illness, including conditions that could interfere with the interpretation of the outcome assessments * pregnant or lactating women * current or recent drug abuse (within past 6 months). * patient refuses regional analgesia. * alcohol or drug abuse

Keywords: radiating back pain epidural block steroid recurrent low back pain lumbar epidural steroid block with 3 injections
cardiac resynchronization therapy, dyspnea and exercise tolerance in patients with congestive heart failure (chf)

Conditions: Congestive Heart Failure

Summary: a new therapy for patients with advanced heart failure (hf) involves the implantation of a specialized pacemaker device (cardiac resynchronization therapy, crt) that attempts to restore the synchronized contraction of the ventricular chambers of the heart. in some people, crt improves exertional breathlessness and allows them to exercise for longer periods. however, to date, the mechanisms by which crt improves symptoms and exercise tolerance is unknown. this study will use in-depth cardiopulmonary exercise testing and pulmonary function testing to explore these mechanisms in greater detail.


Eligibility criteria:
inclusion criteria: * clinically stable * being considered for implantation of biventricular pacemaker for crt * lvef \<35% * qrs duration \>120 msec * nyha iii-iv functional class * optimized pharmacologic management of chf * no recent (\<1 month) episodes of decompensated chf exclusion criteria: * inability to perform cycle ergometry or comply with testing * uncontrolled ischemic heart disease * coronary revascularization within 3 months of study entry * concurrent primary lung disease * current use of ambulatory oxygen * rhythm other than sinus * dependency on pacemaker therapy as a consequence of bradyarrhythmias * severe valvulopathy

Keywords: congestive heart failure cardiac resynchronization therapy dyspnea exercise tolerance
phenotypic and molecular characterisation of cerebral amyloid angiopathy

Conditions: Cerebral Amyloid Aβ Angiopathy

Summary: cerebral aβ amyloid angiopathy is a severe disease characterised by amyloid deposits in the cerebral vessels, manifested mainly by recurrent cerebral haematomas and cognitive impairment. diagnostic criteria are based on brain imaging, but the usefulness of this imaging in predicting the course of the disease remains undetermined. the genetic component is largely understudied. less than 5% of patients carry mutations or duplications of the app gene. susceptibility factors such as apoe genotypes and rare variants recently discovered in alzheimer's disease within the sorl1, trem2 or abca7, abca1 and atp8b4 genes could play a role in the pathophysiology of cerebral amyloid angiopathy. there is currently no specific treatment available. based on a national recruitment of patients with cerebral amyloid angiopathy, this project aims to assess the role of genetic variants in the diagnosis and progression of cerebral amyloid angiopathy. a better understanding of the mechanisms, particularly genetic, could help us to develop treatments in the era of gene therapy.

this research is carried out on the same blood sample taken during the treatment and sent to the rouen university hospital genetics laboratory for research into point mutations or duplication of the app gene as part of the diagnosis of cerebral amyloid angiopathy (caa). for each gene, the proportions of variant carriers will be compared between cases and controls using a fisher exact test with r statistical software. to rule out any population stratification bias, the tests will also be carried out using logistic regression adjusted on the first pca axes (principal component analysis) using the seqmeta function. a bonferroni correction will then be used to adjust the significance threshold according to the number of genes tested.

Eligibility criteria:
inclusion criteria: * patients with a diagnosis of cerebral amyloid angiopathy (caa) whose genetic samples are initially sent to the rouen or paris-lariboisière genetics laboratories for molecular diagnosis of a genetic cause, thanks to national recruitment and for whom the patients consent to continuing genetic analyses for research purposes without feedback. * diagnosis of cerebral amyloid angiopathy (caa) certain or probable according to the modified boston diagnostic criteria (1) (except age) * age of onset of symptoms \<66 years * absence of app mutation/duplication (analysis must already have been carried out in the laboratory on receipt of the sample as part of routine care) * signed consent for research * patient covered by a social security scheme exclusion criteria: * age at first neurological symptom \> 66 years * minor patients * other differential diagnosis that better explains the clinical situation * identification of mutations or duplication of the app gene * aac possible but not probable according to the revised boston criteria * patient deprived of liberty by judicial or administrative decision

Keywords: phenotypic and molecular characterisation